Understanding and Mitigating the Cardiometabolic Risks of ADT
Dr Higano explains how the use of ADT in patients with prostat ecancer may impact metabolic and cardiovascular (CV) risk factors, and shares best practices on optimizing risk assessment, mitigation, and monitoring for these factors.
Part 2_ 1 ADT Backbone Presentation_DrTiaHigano_Mar2023_1
Video Player is loading.
EP: 1.How PSA Has Impacted the Use of ADT in Prostate Cancer
EP: 2.ADT as the Backbone for Combination Treatments in Advanced Prostate Cancer
Now Viewing
EP: 3.Understanding and Mitigating the Cardiometabolic Risks of ADT
EP: 4.Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?
Recent Videos
Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
Protecting Sexual Function Via The Hood Technique in Prostate Cancer
Hood Technique Improves Earlier Continence in Prostate Cancer Surgery
AI Use in Surgeries for Prostate Cancer May Help Standardize Outcomes
Vaccine Trials Ongoing in Locally Advanced Oligometastatic Prostate Cancer
Oncolysis/Immunotherapy Shows ‘Significant’ Data in Prostate Cancer
Tanya B. Dorff, MD, on Phase 1 Trial of CAR T-Cell Therapy in mCRPC
Related Content
Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025Podcast
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
